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Definition of the disease: Behçet disease (BD) is a chronic, relapsing, multisystemic disorder characterized by
mucocutaneous, ocular, vascular and central nervous system manifestations.
Epidemiology: BD seems to cluster along the ancient Silk Road, which extends from eastern Asia to the
Mediterranean basin. European cases are often described, not exclusively in the migrant population.
Clinical description: The clinical spectrum includes oral and genital ulcerations, uveitis, vascular, neurological,
articular, renal and gastrointestinal manifestations.
Etiology: The etiopathogenesis of the disease remains unknown, although genetic predisposition, environmental
factors and immunological abnormalities have been implicated.
Diagnostic methods: Diagnosis is only based on clinical criteria.
Differrential diagnosis: It depends on the clinical presentation of BD, but sarcoidosis, multiple sclerosis, Crohn’s
disease, Takayasu’s arteritis, polychondritis or antiphospholipid syndrome need to be considered.
Management: Treatment is symptomatic using steroids and immunomodulatory therapy. It is efficient depending
on the rapidity of initiation, the compliance, and the duration of therapy.
Prognosis: The prognosis is severe due to the ocular, neurological and arterial involvement.
Keywords: Behçet's disease, Uveitis, Vasculitis, AutoimmunityDuring the annual meeting of the Medical Association of
Athens on November 15, 1930, Benediktos Adamantiades
(1875–1962), Greek ophthalmologist from Prussa (nowadays
Bursa, Turkey), presented in a lecture with the title "A
case of relapsing iritis with hypopyon", a 20-y-old male
patient with the three cardinal signs of the disease [1].
Adamantiades brought the genital ulcers, the arthritis, and
the ocular signs in connection as signs of a single disease
[1]. In 1937 Hulusi Behcet described three patients with oral
and genital ulcerations and hypopyon uveitis. Since then,
due to involvement of central nervous system, large vessels
(veins and/or arteries), heart and rarely gastrointestinal tract
or kidney, Behçet’s disease (BD) is considered as a wide-
spread vasculitis. Behçet’s disease (BD) is a chronic systemic
inflammatory disorder at the crossroad between auto-
immune and autoinflammatory syndromes [2].
International criteria of classification have been defined
with a sensitivity of 85% and specificity of 96% [3] (Table 1).* Correspondence: david.saadoun@psl.aphp.fr
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Cases of BD seem to cluster along the ancient Silk Road,
which extends from eastern Asia to the Mediterranean
basin. The prevalence is 80 to 370 cases per 100,000
population in Turkey, 10/100,000 in Japan and 0.6/
100,000 in Yorkshire. European cases are more often
described, not exclusively in the migrant population. In
common with ankylosing spondylitis and psoriatic
arthropathy, BD has MHC class I associations. HLA-B51
is the most strongly associated known genetic factor to
BD [4]. However, it accounts for less than 20% of the
genetic risk, even in familial cases (less than 5%), which
indicates that other genetic factors remain to be discov-
ered. An association between the BD susceptibility allele
HLAB51 with ocular disease has been reported [5]. A
genetic contribution to BD is also supported by the high
sibling recurrence risk ratio, estimated to be between
11.4 and 52.5 in the Turkish population [6]. The male to
female ratio is 7:1 in symptomatic forms, but women
predominate over men in studies were less symptomatic
forms are systematically looked for and included [7]. BDed Central Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 International Classification Criteria Of Behcet's
Disease
In the absence of other clinical explanations, patients must have:
1. Recurrent oral ulceration (aphthous or herpetiform) observed by the
physician or patient recurring at least three times in a 12-month period;
And two of the following:
2. Recurrent genital ulceration.
3. Eye lesions: anterior uveitis, posterior uveitis, cells in the vitreous by slit
lamp examination or retinal vasculitis observed by an ophthalmologist.
4. Skin lesions: erythema nodosum, pseudofolliculitis, papulopustular lesions
or acneiform nodules in postadolescent patients not on corticosteroids.
5. Pathergy, read by a physician at 24–48 hours.
(Sensibility 85% - Specificity 96%)
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onset cases are reported [8]. After 55 years, onset of BD is
exceptional and diagnosis has to be made very cautiously.
Clinical features
Mucocutaneous lesions
The mucocutaneous lesions constitute the hallmark of BD.
Oral aphthae occur in 98% of cases and are mandatory
in the international criteria of classification. Painful oral
ulcers appear in the tongue, pharynx, buccal and labial
mucosal membranes. They are unique or multiple. The
typical lesion is round with a sharp, erythematous and
elevated border, mostly 1 to 3 cm in diameter, but larger
lesions can also occur. They can start as a raised redness
and soon ulcerate. The surface is covered with a yellow-
ish pseudomembrane. The lesions heal within about 10
days mostly without scarring. Like in all oral aphthoses,
oral ulcers in BD can occur after physical or toxic influ-
ence (dental procedures, simple trauma, or certain foods
such as nuts). When they are numerous or large, eating
and/or speaking it is painful. They evolved to healing
without scarring and/or lymph node swelling. They can
not be differentiated from recurrent oral ulcers but their
number, their size, their recurrence urge to look for the
other manifestations of BD
Genital aphthae occur in 60 to 65% of cases and are
very suggesting of the diagnosis of BD. They are localized
in men on the scrotum, less frequently on the penis or in
the urethra and in women on the vulva and vagina where
they can be disseminated and painful or totally indolent.
They are morphologically similar to the oral ulcers but
usually larger and deeper. The lesions leave scars in 50%
of cases allowing retrospective diagnosis.
The ulcers can also occur on the esophagus, stomach,
small intestine and perianal area, where they can lead to
perforation.
The most frequent skin manifestations are pseudofolliculitis
and erythema nodosum-like lesions. In contrast to acne
vulgaris, pseudofolliculitis and acneiform nodules can appearall over the body and they are not always hair follicle-
associated. Biopsy is useful to demonstrate an inflammatory
infiltrate which is not connected with hair follicle. In our
experience, the diagnosis is not possible when the patient is
treated with steroids. A specific cutaneous irritability is
frequent with papules on site of injections. The pathergy test,
a 2mm papule induced 24 to 48 hours after a cutaneous
pritch, is one of the 4 criteria of classification, but its sensivity
is low with disposable needle and cutaneous disinfection.
Eye manifestations
Ocular involvement is frequent and severe, often bilat-
eral, compromising rapidly the visual function [9,10]. A
variety of eye lesions have been found including anterior
uveitis, cataract, glaucoma, posterior segment involve-
ment with vasculitis, vitritis, retinitis, panuveitis, retinal
edema, cystoid macular degeneration, venous or arterial
occlusion, disc edema and retinal detachment.
Anterior uveitis with hypopyon despite first described
is rare, transient and has a relative good prognosis. It can
be complicated with synechia and glaucoma.
Posterior uveitis is almost constant in case of ocular
involvement. Choroid is first involved with necrosis
lesions. The lesions are peripheral and can lead to
pigmentation. Vitreous body is involved secondarily with
loss of transparency, retraction and traction on the
retina. Fluorescein angiography show capillary dilatation,
vascular obstruction and area of leak. Vasculitis is the
basic process involving veins and arteries with tendency
to thrombosis.
Prognosis is severe due to frequent relapses and partial
recovery with therapy. The poor long-term visual
prognosis is related to ocular hypertension, cataract and
retinal vasculitis with blindness occurring in 25 to 30%
of cases in most series at 5 years. In our experience, with
intensive therapy and careful care simultaneously
realized by ophthalmologist and internist, the prognosis
is much better with only 2% of de novo severe visual loss
at 6 years of follow-up.
The eye involvement may also be associated with
neurological manifestations: cranial nerves palsy, optic
neuropathy or papilledema with benign intracranial
hypertension.
Vascular manifestations
Venous thrombosis occurs in 30% of cases. BD is
included in the wide spectrum of vasculitis. Vasculitis is
a principal pathologic finding in BD, and vessels of all
sizes are involved, both in the arterial and venous
systems.
Venous disease is more common than arterial involve-
ment, and its prevalence may account for 14% to 39% of
patients with BD according to studies. Venous throm-
bosis in BD is a severe disorder, which may affect many
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vena cava, pulmonary artery, supra-hepatic vessels and
cardiac cavities.
Superficial thrombophlebitis are transient and migrant
and sometimes misdiagnosed as erythema nodosum.
Deep vein thrombosis can be seen on various sites but
especially on big vessels: iliofemoral, superior or inferior
vena cava or on unusual localization such as dural
sinus thrombosis (headache, papilledema, intracranial
hypertension), hepatic veins (Budd-Chiari syndrome) or
inferior vena cava with pulmonary aneurysms (Hughes-
Stovin syndrome) [11].
These thrombophlebitis relapses frequently and must
lead to the diagnosis in a young patient without any
other thrombophilic factor. They occur generally in the
first year after onset. Pulmonary embolism is not
frequent, probably due to the inflammatory process on
the endothelial wall of the vessel. In few cases, coinci-
dental thrombophilic factors have been encountered.
The arterial involvement is seen in 3 to 5% of cares
[12]. The incidence is probably underestimated because
an autopsy survey showed that 33% of patients had arter-
ial lesions, most of them had been asymptomatic [11,13].
Thrombosis and/or aneurysms are observed, mainly false
aneurysms [14]. These "arterial aphthae" are localized on
pulmonary arteries, aorta, renal and peripheral arteries.
They can rupture suddenly. Vascular surgery is
mandatory, but thrombosis of the graft and relapses of
aneurysms at the site of bypass are frequent.
The pulmonary aneurysms have a severe prognosis, sur-
gery and/or arterial embolization must be associated with
corticosteroids and immunosuppressive drugs.
Cardiac involvement is also observed and may involve
the 3 tunics [15,16]. Myocarditis, endocarditis with aortic
or mitral insufficiency, fibroblastic endocarditis compli-
cated by intramural thrombosis and relapsing pericarditis
sometimes associated with coronary involvement are
observed. Aneurysms and/or thrombosis of the coronary
arteries are observed complicated by hemorragia, myo-
cardial infarction and sudden death.
Abnormalities of the microcirculation have been
described essentially through capillaroscopy (petechia,
capillary dystrophy) but thet do not have any specificity.
Articular manifestations
Arthralgia and/or arthritis occur in 45% of cases. They
are frequently the presenting feature, long before the
other manifestations. The knees and ankles are most
involved, although smaller joints may also be affected.
X-ray is generally normal. Histologically, there is an infiltra-
tion of neutrophils and mononuclear cells into the
synovium and a vasculitis process on small-vessel with
thrombosis. Association with HLA B27 spondylarthropathy
is seen in 2% of patients. Osteonecrosis of the hip andknees have been observed but most of the patients have
been treated with corticosteroids [17].
Neurologic manifestations
They are observed in 20 to 40% of cases [18]. They may
occur lately, from one to ten years after the first symptom
of BD. Central nervous system involvement in BD
included parenchymal and non-parenchymal (i.e. cerebral
venous thrombosis or arterial aneurism) lesions [19].
Parenchymal lesions of neurobehçet’s disease frequently
onset with an attack rather than a mild progressive course.
They include headache, meningitis or meningoencephal-
itis, seizures, hemiplegia, or cranial nerve palsies. The
benign intracranial hypertension is always related, in our
experience of 64 cases, to cerebral venous thrombosis [20].
Psychiatric symptoms including personality changes may
develop. In some cases it may be difficult to differentiate
the organic manifestations from the iatrogenic side effects
of therapy.
Lumbar puncture with measurement of the open
pressure is mandatory. It usually shows hypercellularity;
mostly lymphocytosis and less frequently polymorpho-
nuclear cells or pleiocytosis. Cerebrospinal fluid analysis
rule out an infection such as tuberculosis, listeriosis or
herpes simplex virus. Typical MRI findings are small
scattered lesions in multiple area of basal ganglion
region, brainstem or internal capsule, with hypersignal in
T2-weighted MRI and contrast enhancement with
Gadolinium. They may attenuate with therapy but a
retrospective diagnosis is generally feasible.
Prognosis is severe but improvement is observed with
intensive and rapid therapy including corticosteroids and
immunosuppressive drugs.
Gastrointestinal manifestations
It is difficult to distinguish between BD and inflamma-
tory diseases of the intestine, because of the similarity in
intestinal and extra intestinal symptoms. This may
explain the discrepancy of frequency ranging from 30%
to 1% [21]. Gastrointestinal involvement causes nausea,
abdominal pain, anorexia, diarrhea which can be bloody
and sometimes can lead to perforation. The ileocecal
region is the most commonly affected part of the gastro-
intestinal tract, but tranverse colon and ascending colon
are sometimes involved, as is the esophagus. Histologi-
cally, the intestinal ulcers are indistinguishable from
Crohn's disease, nevertheless the granuloma formation
can be used to rule out BD. Cases of acute pancreatitis
have been reported.
Pulmonary manifestations
It is dominated by vascular involvement (arterial
aneurysm, pulmonary embolism). Hemoptysis can be
massive and fatal and is the main manifestation [14].
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pulmonary embolism, tuberculosis or nosocomial infec-
tion. Cases of vasculitis have been reported.
Genitourinary manifestations
Renal involvement is rare and dominated by AA amyloid-
osis occuring in patients with long standing disease not
controlled with therapy or not compliant. Some cases of
glomerular nephropathy mostly diffuse crescentic or focal
and segmental necrotizing glomerulonephritis and IgA
nephropathy have been described. Secondary effects of
venous or arterial thrombosis have also been reported.
Epididymitis, occasionally recurrent, occur in 4 to 11%
of patients.
Lymphatic involvement
Lymph or splenic enlargement may exceptionally be the
presenting feature and should be thoroughly evaluated.
When fever is present, vascular involvement has to be
searched for.
Etiopathology
Although the pathogenesis of BD remains poorly under-
stood, it is currently thought, as for many autoimmune
or autoinflammatory syndromes, that certain infectious
(in particular Streptococcus sanguis) and/or environmen-
tal factors are able to trigger symptomatology in indivi-
duals with particular genetic variants [22]. Streptococcal
antigens were shown to increase interleukin (IL)-6 and
interferon (IFN)-γ production by peripheral blood T cells
from BD patients, and cross-react with a 65kD heat
shock protein sharing antigenicity with oral mucosal
antigens [23]. Recently, genome wide association studies
from Japan and Turkey identified an association at
IL23R and IL12RB2 locus [24,25]. The implication of T
cells and polymorphonuclear leukocytes is supported by
pathological studies showing perivascular infiltration of
memory T cells and polymorphonuclear leucocytes
within vasculitic lesions in BD patients with arterial and
central nervous system (CNS) involvement [26,27].
However, the nature of T cells driving inflammatory
lesions remains elusive. We recently demonstrated the
promotion of Th17 responses and the suppression of
regulatory T cells (Tregs) that were induced by interleu-
kin (IL)-21 production and that correlates with BD
activity [28]. We demonstrated the presence of IL-21
and IL-17A-producing T cells within cerebrospinal fluid
(CSF), brain parenchyma inflammatory infiltrates, and
intracerebral blood vessels from active BD patients with
central nervous system (CNS) involvement. Stimulation
of CD4+ T cells with IL-21 increased Th17 and Th1
differentiation and decreased Tregs frequency. Con-
versely, IL-21 blockade with an IL-21R-Fc restored the
Th17 and Treg homeostasis in BD patients. Our findingssuggest that IL-21 exerts a critical role in the pathogen-
esis of BD, thus providing a promising target for novel
therapy [28].
Diagnosis
In BD there is no relevant biological test for diagnosis.
International criteria of classification have been defined
with a sensitivity of 85% and specificity of 96% [3]. The
erythrocyte sedimentation rate, CRP and other acute
phase reactants are seldom elevated during the acute
phase and/or relapses of BD but are not well correlated
with disease activity. Abnormalities of fibrinolysis,
elevated factor VIII, immune circulating complexes and
cryoglobulinemia have been occasionally reported.
Leucocytosis is frequently encountered. The positivity of
HLA B 51 allele is of no diagnostic value. Cutaneous
biopsy of intradermal injection with physiologic saline
solution may demonstrate vasculitis with immune
complexes deposit.
Differential diagnosis
The diagnosis of BD is only supported by clinical criteria
that require the exclusion of other diagnoses based on
clinical presentation. Oral ulceration is not specific of
BD as it may occur in 30-40% of the general population.
In contrast, bipolar ulcerations are more specific of BD.
Oral ulcerations may also be associated with hemopathy,
HIV, Crohn’s disease, lupus, bullous dermatosis or vitamin
deficiencies. Sarcoidosis, Crohn’s disease, Vogt-Koyanagi
Harada and infectious uveitis must be ruled out in case of
recurrent uveitis.
Venous involvement should exclude the antiphospholipid
syndrome, or thrombophilia. Arterial lesions of BD may
mimic Takayasu’s arteritis or polychondritis. Neuro-BD is
sometimes difficult to distinguish from multiple sclerosis or
tuberculosis. Lastly, chronic inflammatory bowel disorders
must be ruled out in case of gastrointestinal involvement.
Management
Due to the lack of an etiologic agent, the treatment is
symptomatic without consensus. EULAR recommenda-
tions for the management of BD, based on the available
literature and expert opinions, have been recently
proposed [29]. The goals are the functional recovery of a
visceral involvement (eye, CNS) and prevention of relapse
(s). The risks of BD are an increased mortality especially
in case of arterial involvement, and a high morbidity due
to the cumulative sequellae of ocular and neurological
involvement [7,30]. Steroids are the corner stone of the
antiinflammatory agents administered topically (anterior
uveitis) or systemically. A general consensus is obtained
for their prescription in case of ocular and/or central
nervous system involvement at a dosage of 1mg/kg/day.
Initiation of therapy could be made by infusion of
Saadoun and Wechsler Orphanet Journal of Rare Diseases 2012, 7:20 Page 5 of 6
http://www.ojrd.com/content/7/1/20methylprednisolone (1 g.) during the first three days.
When steroids are used, they can be reduced with caution
after 4 weeks. Relapses are frequently seen after discon-
tinuation of steroids. Corticodependance is frequently
observed. Immunosuppressive drugs have been shown to
be effective. Due to their delay of action, they are
prescribed initially in association with corticosteroids. They
are prescribed in cases of severe organ involvement
(i.e. posterior uveitis, CNS involvement, vascular
involvement. . .). Azathioprine (2.5 mg/kg/day) was proved
effective in a controlled study [31]; cyclophosphamide
orally (2 mg/kg/day) or intravenously (750 to 1g/m2 every
4 weeks) is also used. The efficacy of oral methotrexate (7.5
mg once a week) has also been reported. Chloraminophen
(0.1 to 0.2 mg/kg/day) is less presribed due to its
hematological side effects. Ciclosporin was proved effective
in uveitis [29], but secondary nephropathy limits its
prescription. More recently the efficacy of infliximab
has been reported in severe cases of BD uveitis [32].
Plasmapheresis and intravenous immunoglobulins were
efficient in anecdotal reports. Alpha interferon (2a or 2b) is
also efficient, especially in case of severe and/or resistant
uveitis [33].
We usually prescribe antiagregant therapy or anticoa-
gulation in case of vascular involvement.
Colchicine (1-2mg/day) has beneficial effects on the
mucocutaneous symptoms decreasing the number, size
and recurrence of aphthae [34]. We used it systematically
in adjunction with other therapeutic agents. Severe flares
of BD were observed after cessation of this drug.
Thalidomide is also reported to be effective for oral and
genital ulcers and pseudofolliculitis with relapses when
stopped [35]. Contraceptive measures are mandatory
due to severe fœtal malformation. Among side effects,
peripheral neuropathy is frequent.
Disulone, Sucralfate, and Pentoxifylline have shown
some efficacy in anecdotal reports [36,37].
As for other chronic diseases, patient education, good
compliance, regular follow-up and rapid therapeutic
administration improve the prognosis.
Prognosis
BD significantly increases morbidity and mortality. The
leading causes of morbidity in BD are the uveitis with
the potential threat of visual loss and neurologic involve-
ment. Few, studies have addressed the mortality of
Behçet syndrome. Among 2,031 patients from Japan,
31.7% were clinically deteriorated, and 0.9% died during
the course of a single year’s follow-up. In Turkey, 42
patients out of 428 died mainly due to major vessel
disease and neurologic involvement. We recently
reported that among 817 BD patients, 41 (5%) died after
a median follow-up of 7.7 years [7]. The mean (± SD)
age at death was 34.6 ± 11.5 years with 95.1% of male.Main causes of death included major vessel disease
(mainly arterial aneurysm and Budd-Chiari syndrome)
(43.9%), cancer and malignant hemopathy (14.6%), and
central nervous system involvement and sepsis (12.2%).
The mortality rate at 1 and 5 years was of 1.2% and
3.3%, respectively. There was an increased mortality
among the 15–24 years [SMR with 95% confidence inter-
val, 2.99 (1.54-5.39)], and the 25–34 years, [SMR 2.90
(1.80-4.49)] as compared to age and sex matched healthy
controls. The mortality decreased in patients older than
35 years [SMR, 1.23 (0.75-1.92)]. In multivariate analysis,
male gender (HR: 4.94, CI: 1.53-16.43), arterial involve-
ment (HR: 2.51, CI: 1.07-5.90), and a high number of BD
flare (HR: 2.37, CI: 1.09-5.14) were independently asso-
ciated with mortality [7].
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